

July 9, 2020

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Scrip code: 532531

Dear Madam/Sir,

Subject: Press Release

Please find attached Press Release issued by the Company titled:

"Strides receives USFDA approval for Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules"

Thanking you,

Yours faithfully,

For Strides Pharma Science Limited

Manjula Ramamurthy Company Secretary

Encl. As above



(Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex

Bandra (E) Mumbai - 400 051

Scrip code: STAR

info@strides.com; www.strides.com



Strides receives USFDA approval for Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules

To be marketed by Strides Pharma Inc. in the US market

Bangalore, July 09, 2020 - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for *Butalbital*, *Acetaminophen*, *Caffeine*, *and Codeine Phosphate Capsules*, 50 mg/325 mg/40 mg/30 mg from the United States Food & Drug Administration (USFDA). The product is a generic version of Fioricet® with Codeine Capsules, 50 mg/325 mg/40 mg/30 mg, of Teva Branded Pharmaceutical Product R&D, Inc.

According to IQVIA MAT May 2020 data, the US market for Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, 50 mg/325 mg/40 mg/30 mg is approximately US\$ 10 Mn. The product will be marketed by Strides Pharma Inc. in the US market.

The company has 124 cumulative ANDA filings with USFDA of which 87 ANDAs have been approved and 37 are pending approval.

About Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules

Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules is indicated for the relief of the symptom complex of tension (or muscle contraction) headache.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available at the Company's website at www.strides.com

For further information, please contact:

Strides Badree Komandur Executive Director - Finance +91 80 6784 0747

Corporate Communication
Usha lyer: +91 9987444106
Email: usha.iyer@strides.com

Investor Relations

Kannan. N: +91 98450 54745

Sandeep Baid: +91 80 6784 0791

Email: Sandeep.baid@strides.com

Strides Pharma Science Limited

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17,

Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta

Road, Bangalore – 560 076

PR Consultancy

Fortuna PR

K Srinivas Reddy: +91 90005 27213

srinivas@fortunapr.com

K Priya: +91 95354 25418

priya@fortunapr.com